BioSpace News Archive

bioLytical Laboratories Inc., a global leader in rapid in-vitro medical diagnostics, announced that it has received Health Canada authorization for its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test, allowing its immediate entry into the Canadian market.

Alimera Sciences, Inc. announces a series of strategic transactions bolstering its balance sheet, extending its current term loan facility, and recovering value for common stockholders.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s climate goals.

POINT Biopharma Global Inc. today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the FDA approved enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial.

BIORCHESTRA announced an exclusive research, option, and licensing agreement with a global biopharmaceutical company focused on developing transformative medicines.

Vertex Pharmaceuticals Incorporated today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).

Immusoft today announced that it has successfully closed a license with the Regents of the University of Minnesota for the exclusive, worldwide rights to intellectual property (IP) for compositions of matter and methods to make and use genome edited primary B cells.

Imvax, Inc. today announced dosing of the first patient in the company’s randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM).

OliX Pharmaceuticals, Inc. today announced that the first patient has been successfully dosed in a Phase 1 clinical trial ( NCT05643118 ), evaluating OLX10212, an investigational RNAi therapeutic intended for the treatment of age-related macular degeneration (AMD), including geographic atrophy (GA) and neovascular (nv) AMD.